Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Oct;40(10):2243-2248.
doi: 10.1007/s10096-021-04305-3. Epub 2021 Jul 13.

Prognosis of rash and chilblain-like lesions among outpatients with COVID-19: a large cohort study

Hélène Mascitti  1 , Patrick Jourdain  2 , Alexandre Bleibtreu  3 , Luc Jaulmes  4 , Agnès Dechartres  5 , Xavier Lescure  6 , Youri Yordanov  7 , Aurélien Dinh  8 ; AP-HP/Universities/INSERM COVID-19 research collaboration
Collaborators, Affiliations
Observational Study

Prognosis of rash and chilblain-like lesions among outpatients with COVID-19: a large cohort study

Hélène Mascitti et al. Eur J Clin Microbiol Infect Dis. 2021 Oct.

Abstract

In a large regional observational cohort study of adult (≥ 18 years), outpatients with COVID-19, prevalence, characteristics, and outcome of patients with rash and/or chilblain-like lesions (CLL), compared with population without cutaneous features, were studied. In total, 28,957 outpatients were included; the prevalence of rash and CCL were 9.5% and 3.7%, respectively. Presence of rash was significantly associated with presence of asthenia, shivers or myalgia, respiratory and gastro-intestinal symptoms, and anosmia/ageusia. The presence of CCL was associated with chest pain, chest oppression, nausea/vomiting, and anosmia/ageusia. Patients with CCL were significantly less prone to an unfavourable outcome (hospitalization or death).

Keywords: COVID19; Chilblain-like lesion; Hospitalization; Rash; Risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart
Fig. 2
Fig. 2
Selected adjusted odd ratios and confidence intervals from multivariate analysis of characteristics associated with rash or chilblain-like lesions among outpatients with COVID19
See this image and copyright information in PMC

References

    1. Herman A, Peeters C, Verroken A, Tromme I, Tennstedt D, Marot L et al (2020) Evaluation of chilblains as a manifestation of the COVID-19 pandemic. JAMA Dermatol 1(156):998. https://doi.org/10.1001/jamadermatol.2020.2368. https://jamanetwork.com/journals/jamadermatology/fullarticle/2767774 - PMC - PubMed
    1. Matar S, Oulès B, Sohier P, Chosidow O, Beylot‐Barry M, Dupin N et al (2020) Cutaneous manifestations in SARS‐CoV‐2 infection (COVID‐19): a French experience and a systematic review of the literature. J Eur Acad Dermatol Venereol 20. 10.1111/jdv.16775. Ahead of print. https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16775 - DOI - PMC - PubMed
    1. Mascitti H, Bonsang B, Dinh A, Assan F, Perronne V, Leblanc T et al (2020) Clinical cutaneous features of patients infected with SARS-CoV-2 hospitalized for pneumonia: a cross-sectional study. Open Forum Infect Dis 7. 10.1093/ofid/ofaa394. https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofaa394/5... - DOI - PMC - PubMed
    1. Yordanov Y, Dechartres A, Lescure X, Apra C, Villie P, Marchand-Arvier J et al (2020) Covidom, a telesurveillance solution for home monitoring of patients with Covid-19. (Preprint). J Med Internet Res. 10.2196/20748. http://preprints.jmir.org/preprint/20748/accepted - PMC - PubMed
    1. Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J (2020) Cutaneous manifestations in COVID‐19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol 34. 10.1111/jdv.16530https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16530 - DOI - PMC - PubMed

Publication types